The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells

One of the most significant therapeutic challenges in the treatment of ovarian cancer is the development of recurrent platinum-resistant disease. Cancer stem cells (CSCs) are postulated to contribute to recurrent and platinum-resistant ovarian cancer (OvCa). Drugs that selectively target CSCs may au...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellio, Chiara, DiGloria, Celeste, Spriggs, David R., Foster, Rosemary, Growdon, Whitfield B., Rueda, Bo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896080/
https://www.ncbi.nlm.nih.gov/pubmed/31671803
http://dx.doi.org/10.3390/cancers11111678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896080/
https://www.ncbi.nlm.nih.gov/pubmed/31671803
http://dx.doi.org/10.3390/cancers11111678

Ejemplares similares